Candel Therapeutics, Inc.

NASDAQ (USD): Candel Therapeutics, Inc. (CADL)

Last Price

7.81

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

0

Overview

Market Cap

347 Million

Shares Outstanding

44 Million

Avg Volume

3,930,391

Avg Price (50 Days)

6.85

Avg Price (200 Days)

6.73

PE Ratio

-4.51

EPS

-1.73

Earnings Announcement

27-Mar-2025

Previous Close

7.15

Open

7.18

Day's Range

7.18 - 7.92

Year Range

1.21 - 14.6

Trading Volume

969,352

Price Change Highlight

1 Day Change

9.23%

5 Day Change

14.68%

1 Month Change

-15.29%

3 Month Change

50.19%

6 Month Change

53.44%

Ytd Change

-13.13%

1 Year Change

491.67%

3 Year Change

87.29%

5 Year Change

11.57%

10 Year Change

11.57%

Max Change

11.57%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment